donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 09969 INNOCARE-B > Company Profile
09969 INNOCARE-B
14.200
+0.100+0.71%
Symbol
09969
Company Name
INNOCARE-B
ISIN
KYG4783B1032
Listing Date
03/23/2020
Establishment Date
11/03/2015
Registration
Cayman Islands
Chairman
Jisong Cui
Secretary
Xiepeishan Li
Audit Institution
Ernst & Young accounting firm
Company Category
Overseas registration of Mainland Individuals control
Registered Office
Office of Ogier Global (Cayman) Limited 89 Nexus Way Camana Bay Grand Cayman, KY1-9009 Cayman Islands
Head Office and Principal Place of Business
40 / F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong
Fiscal Year Ends
12-31
Employees
721
Market
Hong Kong motherboard
Phone
(86)1066609999
Fax
(86)1060702992
Email
IR@innocarepharma.com
Business
Nuocheng Jianhua Pharmaceutical Co., Ltd. is an investment holding company mainly engaged in biomedical business. The company discovers, develops and commercializes potentially best-in-class and pioneered drugs for the treatment of cancer and autoimmune diseases. The company has established an integrated biomedical platform with internal research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, as well as commercial production and sales.
Profile
Rooted in China, a leading biomedical company with an integrated biomedical platform. Who are we? We are committed to discovering, developing and eventually commercializing best-in-class or first-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of experienced industry executives, we have established an integrated biomedical platform with strong internal R & D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, as well as commercial production and sales. Based on the leading global vision and strong execution capability of our management team, we have a balanced pipeline portfolio. Our drug candidates are targeted at proven or novel biological pathways. Our strategy is to focus on developing treatments for cancer and autoimmune diseases-two areas of treatment with significant market opportunities and synergies. Our vision is to become a biomedical leader in developing and providing innovative treatments for patients around the world.
Company Overview
Nuocheng Jianhua Pharmaceutical Co., Ltd. is an investment holding company mainly engaged in biomedical business. The company discovers, develops and commercializes potentially best-in-class and pioneered drugs for the treatment of cancer and autoimmune diseases. The company has established an integrated biomedical platform with internal research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, as well as commercial production and sales.
CEO: Jisong Cui
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...